This novel scientific approach offers the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications. Microcures has created a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. Unlike regenerative medicine approaches that rely upon engineered materials or systemic growth factor/stem cell therapeutics, MicroCures’ technology directs and enhances the body’s inherent healing processes through local, temporary modulation of cell motility.
MicroCures is rapidly advancing its lead candidate, siFi2, for excisional wound healing, a multi-billion dollar market that is inadequately served with current treatment options. Multiple preclinical studies have demonstrated that the company’s technology produced statistically significant improvement and acceleration of wound repair.
Based on these findings, MicroCures expects to file an investigational new drug (IND) application in 2020 and initiate a Phase 1 clinical trial thereafter. The company’s pipeline also includes follow-on cell motility acceleration programs focused on burn healing, nerve regeneration and cardiac repair, as well as earlier-stage cell motility deceleration work designed to combat cancer metastases and fibrosis.